CymaBay Therapeutics (CBAY) Receives U.S. Patent Related to MBX-8025

October 11, 2016 8:03 AM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,381,181. This patent provides coverage to at least 2035 and claims methods of treating NAFLD and NASH comprised of orally administering a therapeutically effective amount of MBX-8025.

“This patent provides CymaBay with important additional intellectual property protection for MBX-8025, expanding it to the treatment of NASH, a disease with increasing prevalence and no currently approved therapies,” said Harold Van Wart, CymaBay’s President and Chief Executive Officer.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Litigation

Add Your Comment